VYGR Quote, Financials, Valuation and Earnings

Mersana Therapeutics has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -86.29%. Voyager Therapeutics's return on equity of -21.07% beat Mersana Therapeutics's return on equity of -533.43%.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 363.98%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.71 which suggests that it could grow by 1195.49%. Given that Mersana Therapeutics has higher upside potential than Voyager Therapeutics, analysts believe Mersana Therapeutics is more attractive than Voyager Therapeutics.

Voyager Therapeutics has a beta of 1.018, which suggesting that the stock is 1.773% more volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.275%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than Mersana Therapeutics quarterly revenues of $16.4M. Voyager Therapeutics's net income of -$34.5M is lower than Mersana Therapeutics's net income of -$14.1M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.50x versus 1.10x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -2.16%. Voyager Therapeutics's return on equity of -21.07% beat Myomo's return on equity of -48.64%.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 363.98%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 91.12%. Given that Voyager Therapeutics has higher upside potential than Myomo, analysts believe Voyager Therapeutics is more attractive than Myomo.

Voyager Therapeutics has a beta of 1.018, which suggesting that the stock is 1.773% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than Myomo quarterly revenues of $12.1M. Voyager Therapeutics's net income of -$34.5M is lower than Myomo's net income of -$260.1K. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.50x versus 5.61x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -489.18%. Voyager Therapeutics's return on equity of -21.07% beat Sutro Biopharma's return on equity of -204.67%.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 363.98%. On the other hand Sutro Biopharma has an analysts' consensus of $3.43 which suggests that it could grow by 279.86%. Given that Voyager Therapeutics has higher upside potential than Sutro Biopharma, analysts believe Voyager Therapeutics is more attractive than Sutro Biopharma.

Voyager Therapeutics has a beta of 1.018, which suggesting that the stock is 1.773% more volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.657%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than Sutro Biopharma quarterly revenues of $14.8M. Voyager Therapeutics's net income of -$34.5M is higher than Sutro Biopharma's net income of -$72.4M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.50x versus 1.12x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -296.76%. Voyager Therapeutics's return on equity of -21.07% beat Zevra Therapeutics's return on equity of -208.85%.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 363.98%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 200.35%. Given that Voyager Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Voyager Therapeutics is more attractive than Zevra Therapeutics.

Voyager Therapeutics has a beta of 1.018, which suggesting that the stock is 1.773% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.938, suggesting its more volatile than the S&P 500 by 93.751%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Voyager Therapeutics's net income of -$34.5M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.50x versus 14.10x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.